Ulrik Niels Lassen

Ulrik Niels Lassen

Clinical Professor

Member of:

  • Clinical Oncology


Publication year:
All
1 - 7 out of 7Page size: 10
  1. 2015
  2. Published

    The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2

    Alanin, M. C., Klausen, C., Cayé-Thomasen, Per, Thomsen, C., Fugleholm, K., Poulsgaard, L., Lassen, Ulrik Niels, Mau-Sorensen, M. & Hofland, K. F., Dec 2015, In: European Archives of Oto-Rhino-Laryngology. 272, 12, p. 3627-3633 7 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  3. Published

    Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

    Lokhorst, H. M., Plesner, T., Laubach, J. P., Nahi, H., Gimsing, P., Hansson, M., Minnema, M. C., Lassen, U., Krejcik, J., Palumbo, A., van de Donk, N. W. C. J., Ahmadi, T., Khan, I., Uhlar, C. M., Wang, J., Sasser, A. K., Losic, N., Lisby, S., Basse, L., Brun, N. & 1 others, Richardson, P. G., 24 Sep 2015, In: New England Journal of Medicine. 373, 13, p. 1207-19 13 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  4. Published

    Decline in CA19-9 during chemotherapy predicts survival in four independent cohorts of patients with inoperable bile duct cancer

    Grunnet, M., Christensen, I. J., Lassen, Ulrik Niels, Jensen, L. H., Lydolph, M., Knox, J. J., McNamara, M. G., Jitlal, M., Wasan, H., Bridgewater, J., Valle, J. W. & Mau-Sørensen, M., Jul 2015, In: European journal of cancer (Oxford, England : 1990). 51, 11, p. 1381-8 8 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  5. Published

    Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma

    Lassen, Ulrik Niels, Chinot, O. L., McBain, C., Mau-Sørensen, M., Larsen, V. A., Barrie, M., Roth, P., Krieter, O., Wang, K., Habben, K., Tessier, J., Lahr, A. & Weller, M., Jul 2015, In: Neuro-Oncology. 17, 7, p. 1007-15 9 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  6. A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3

    Mau-Sørensen, M., Dittrich, C., Dienstmann, R., Lassen, Ulrik Niels, Büchler, W., Martinius, H. & Tabernero, J., May 2015, In: Cancer Chemotherapy and Pharmacology. 75, 5, p. 1065-73 9 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  7. Published

    A phase I monotherapy study of RG7212, a first-in-class monoclonal antibody targeting TWEAK signaling in patients with advanced cancers

    Lassen, Ulrik Niels, Meulendijks, D., Siu, L. L., Karanikas, V., Mau-Sorensen, M., Schellens, J. H. M., Jonker, D. J., Hansen, A. R., Simcox, M. E., Schostack, K. J., Bottino, D., Zhong, H., Roessler, M., Vega-Harring, S. M., Jarutat, T., Geho, D., Wang, K., DeMario, M. & Goss, G. D., 15 Jan 2015, In: Clinical Cancer Research. 21, 2, p. 258-66 9 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  8. Published

    18F-FET microPET and microMRI for anti-VEGF and anti-PlGF response assessment in an orthotopic murine model of human glioblastoma

    Nedergaard, M. K., Michaelsen, Signe Regner, Urup, T., Broholm, H., El Ali, Henrik H., Poulsen, H. S., Stockhausen, M., Kjær, Andreas & Lassen, Ulrik Niels, 2015, In: P L o S One. 10, 2, p. 1-16 16 p., e0115315.

    Research output: Contribution to journal › Journal article › Research › peer-review

ID: 4952653